This review examines current evidence for baseline functional impairment and changes with therapy in patients with peripheral arterial disease (PAD) -ranging from patients without claudication or critical limb ischemia (CLI) but other exertional leg symptoms (erroneously referred to as asymptomatic in the Fontaine classi cation system), to patients with claudication and those with CLI. The review points out that the status of functional outcomes research is markedly different in focus and development in the different levels of disease severity -paradoxically less studied in the more severe CLI population than in patients with claudication, for example.
Background
Patients with peripheral arterial disease (PAD) have traditionally been classi ed according to severity of symptoms into Fontaine levels I through IV. 1 However, recent research has demonstrated that this classi cation scheme may not represent the full range of patients with PAD in terms of functional status. For instance, it is well known that claudication results in a limitation of ambulatory activities and an impairment of functional status and quality of life. 2 -6 However, patients who do not experience claudication but have other exertional leg symptoms do not fall neatly into any of the existing classes. These patients have typically been included in the Fontaine I class, which is considered to represent asymptomatic persons with PAD, but many of these patients are actually not asymptomatic and in fact show a signi cant degree of impairment. 7 -1 2 Thus, this report will not use the Fontaine stages for describing functional impairment across the stages of disease severity in PAD but will use a more empiric approach to describe the abnormalities. We will therefore describe impairment in functional status/health-related quality of life and treatments (when available) of: asymptomatic patients with PAD, patients with exertional leg symptoms other than claudication, patients with claudication, and patients with critical limb ischemia.
Another important issue is that the status of research in the various stages of PAD differs with disease severity. The functional impairment of persons with claudication has been most thoroughly characterized among the stages of disease severity in PAD. In addition, treatments to relieve the disability of claudication have been well described, although many questions remain in terms of optimal therapy. In contrast, although the impairments caused by exertional leg symptoms other than claudication have been well characterized, treatments have not yet been speci cally developed to address this problem. The functional status/health-related quality of life effects of critical limb ischemia (CLI) have not been as well established as for claudication. CLI is associated with severe functional impairment, but most of the current therapies also involve signi cant additional short-and/or long-term morbidity. Therefore, the real question in this population is weighing the potential functional bene ts of therapy (usually limb salvage) against the functional detriment of the morbidity of therapy (multiple procedures, wound healing, procedural mortality, etc.). For instance, although amputation can impose severe functional impairment, there are cases where amputation appears to be associated with an improvement in quality of life rather than the opposite. Understanding these issues is clearly of great importance. With increasing limitations both on third party reimbursement for procedures and large health plan pharmaceutical formularies, identifying the degree of functional impairment in these patients and the extent to which functional impairment can be improved with therapy is imperative. This review will therefore summarize available data on functional status and quality of life evaluation in patients with PAD according to symptoms rather than Fontaine status. In addition, important areas for future study are discussed.
Epidemiology PAD affects an estimated 8-10 million Americans and is associated with a three to sixfold increased risk of cardiovascular morbidity and mortality as compared to individuals without PAD. 1 3 -1 6 Types of leg symptoms commonly encountered in PAD In epidemiological studies, the majority of PAD patients who do not have classical symptoms of intermittent claudication have typically been lumped in the category termed 'asymptomatic' PAD. Recent work by McDermott et al, 9 -1 1 Criqui et al, 7 Newman et al 1 2 and Hirsch et al 8 have shown that in fact most of these PAD patients are not truly asymptomatic but often have exertional leg symptoms which differ from claudication but still impose signi cant functional limitations. The prevalence of exertional leg symptoms other than claudication varies from approximately 30% to 45% among patients with PAD ( Table 1) .
The classical symptom of intermittent claudication is exertional calf pain that resolves within 10 minutes of rest. The prevalence of claudication in a documented PAD popu- lation ranges from approximately 10% in groups identi ed from community-dwelling and general medical settings to approximately 33% among groups identi ed from noninvasive vascular laboratories. 7 Critical limb ischemia may be de ned as acute or chronic ischemic rest pain, or chronic ulceration and/or gangrene, attributable to objectively proven arterial occlusive disease. 1 The incidence of CLI has been calculated to be in the order of 1 per 2000 population per year, 1 7 of which up to 30% have diabetes. Approximately 5-10% of patients identi ed from a medical center with PAD have CLI. 1 8 Assessing quality of life and functional status in this group is especially challenging since symptoms may change rapidly, patients commonly undergo surgical therapy with abrupt changes in function, and patients often have abbreviated survival so that long-term follow-up is frequently not possible. Thus, many questions remain in terms of functional assessment as well as treatment of this group. These questions are important to answer since decisions about procedures such as amputation versus aggressive revascularization could be markedly in uenced.
The common methods of functional assessment in PAD are listed in Appendix I.
Status of knowledge about functional status/health-related quality of life in patients with PAD PAD patients without classical intermittent claudication symptoms As described above, men and women who have PAD without classical symptoms of intermittent claudication are either asymptomatic or have exertional leg symptoms other than intermittent claudication. Characterization of functional impairment in these groups has occurred fairly recently. Treatments for the functional impairments in these patients have not been developed, partly as a consequence of the recent nature of the characterization. Thus, the functional impairments are summarized below without discussion of treatment.
Asymptomatic patients
Data from the Women's Health and Aging Study (WHAS) 1 0 has helped de ne the relationship between asymptomatic PAD (de ned as absence of exertional leg pain) and lower extremity functioning. The WHAS was a study of 1002 disabled women age 65 and older living in and around Baltimore. Of 933 women with valid ankle brachial index (ABI) measurements, 35% had ABI-de ned PAD (<0.090). Of those, 67% had asymptomatic PAD. Compared with women with normal ABI values, those with lower ABI values had greater dif culty walking one-quarter mile (400 m) and walked fewer city blocks during the last week. Lower ABI values were also associated with poorer performance on objective measures of leg functioning, including walking speed, standing balance and time for ve rises from a seated position. All of these associations were maintained after adjusting for known and potential confounders. In contrast, there were no signi cant associations between ABI level and upper extremity functioning, suggesting that lower extremity arterial ischemia does not cause global impairment in functioning, but speci cally impairs lower extremity functioning. While WHAS demonstrated that asymptomatic PAD was associated with signi cant functional impairment among community-dwelling individuals, a limitation of this study was that all participants were disabled women age 65 and older.
In the Walking and Leg Circulation Study (WALCS), McDermott et al 1 1 studied clinical characteristics and functional impairment associated with speci c leg pain categories in men and women with PAD identi ed from three noninvasive vascular laboratories in Chicago. The asymptomatic category was subdivided as follows. An asymptomatic 'active' group was de ned that included PAD patients without exertional leg pain who walked more than six blocks last week. An asymptomatic 'inactive' group consisted of PAD patients without exertional leg pain who walked six or fewer blocks last week. De ning these two groups of asymptomatic PAD patients facilitated comparisons between PAD persons who may be asymptomatic because of severely reduced physical activity (the asymptomatic 'inactive' group) versus those who may be asymptomatic because they have a more mild form of PAD (the asymptomatic 'active' group). Compared with PAD participants with claudication, the two groups of asymptomatic PAD participants in WALCS were signi cantly older. The inactive asymptomatic PAD group included a signi cantly higher prevalence of African-Americans than with the claudication group in the WALCS.
Functional measures in the WALCS included 6-minute walk performance, usual and fast pace walking speed over 4 m, and standing balance (Appendix I). The asymptomatic inactive group had signi cantly slower walking speed than the intermittent claudication group, adjusting for confounders. During the 6-minute walk test, 33% of the asymptomatic-active group and 54% of the asymptomatic-inactive group developed exertional leg pain. This nding suggests that many asymptomatic PAD patients do not get exertional leg symptoms because they limit their activity to levels beneath the threshold where symptoms develop.
Patients with exertional leg symptoms other than claudication
Of the 460 PAD participants in the WALCS, 1 1 32% had leg symptoms consistent with claudication and 48% had exertional leg symptoms other than claudication. Nineteen per cent of WALCS participants with PAD had exertional leg pain that sometimes began at rest (pain on exertion and rest), 9% had exertional leg symptoms that did not cause them to stop walking (atypical leg pain/carry on), and 20% had other exertional leg pain that was not consistent with classical claudication (atypical exertional leg pain/stop). The atypical exertional leg pain/carry on group had higher average ABI levels than patients with claudication. Participants with exertional leg pain/carry-on included a higher proportion of men and had fewer comorbidities and better functioning than participants with claudication. In contrast, PAD participants with leg pain on exertion and rest included a higher proportion of women, had a higher number of comorbidities, and had poorer functioning than PAD participants with claudication. Compared with participants with claudication, the leg pain on exertion and rest group had more neuropathy and a higher prevalence of comorbid diseases in uencing leg symptoms such as spinal stenosis and diabetes mellitus ( Table 2 ). The ndings suggest that comorbid conditions probably contribute to the exertional leg symptoms of this group of PAD patients.
Future directions
Functional impairment is present in PAD patients who do not have classical symptoms of claudication. In some cases, functional impairment is greater than among PAD patients with classical claudication. Further study is needed to de ne the natural history of functional impairment in PAD patients who do not have classical symptoms of intermittent claudication and to identify clinical characteristics associated with greater functional decline over time. Future study is also needed to identify interventions that improve lower extremity functioning in PAD patients without classical intermittent claudication. Pain on exertion and rest were considered present when the following two questions from the San Diego claudication questionnaire were answered 'yes' for the same leg: (1) Do you get pain in either leg or either buttock on walking? (2) Does this pain ever begin when you are standing still or sitting? Thus, patients with pain on exertion and rest have leg pain that begins with walking but also sometimes begins with rest (i.e., both conditions 1 and 2 are met).
Patients with claudication
The walking impairment resulting from claudication is often of a magnitude that leads to further limitations in physical, social, leisure and occupational functioning. Patients with claudication are compromised in their ability to carry out daily activities and are further troubled with a sense of inadequacy. They consider the symptoms a 'burden' on them and their families. 1 9 In contrast to other symptoms of PAD, treatments for claudication have been studied extensively and their impact on functional status is included below. It is apparent that claudication causes severe disability. In a study of patients with claudication by Hiatt et al, patients reported having a 50% decrease in the ability to walk speci c distances and speeds due to their claudication compared with normal age-matched controls. 2 0 In addition, physical activity and physical functioning were decreased as well. 6 Several other studies have reported similar ndings. Pell reported that compared with population norms, all functional status/health-related quality of life scores were lower in the patient with claudication. 5 Khaira et al reported that patients with claudication have greater perceived problems in the areas of energy, pain, emotional reactions, sleep and physical mobility than healthy controls. 4 Patients with claudication who were interviewed about the impact of PAD on their lives reported signi cant limitations in physical and social functioning, feelings of uncertainty and fear, and a sense of compromise of self as a result of this disease. 1 9 As a whole, the data show that claudication has adverse effects both on functional status and quality of life, as well as ambulatory ability specically.
It is important to note that patients with claudication often have comorbid conditions that may play a large role in quality of life impairment. While functional outcomes pre-and postclaudication interventions are most easily interpreted in patients for whom the primary limiting factor functionally is claudication, this issue limits generalizability. Assessments of functional status and quality of life have been performed and reported in claudicating patients who have received exercise rehabilitation, peripheral bypass surgery, angioplasty and pharmacologic therapy. Representative data from each approach are reported below.
Exercise rehabilitation
To our knowledge, all studies of supervised exercise conditioning in persons with PAD have reported an increase in graded treadmill exercise performance, and a reduction of claudication pain severity during exercise. 6 ,2 0 -2 2 The improvement in pain-free walking time ranged from 44% to 300%, while maximal walking time increased from 25% to 442%. Thus, exercise training improves the ability to walk on a treadmill without claudication for longer distances and also for longer absolute periods of time. The consistency of ndings suggests that supervised exercise training programs have a clinically important impact on functional capacity in claudicating patients.
Several randomized trials that have evaluated the ef cacy of exercise rehabilitation have assessed change in functional status using questionnaire assessment. 2 0 , 2 1 In one study, 20 people with claudication were randomly assigned to be in either a walking exercise group or a nonexercising control group. 2 1 The exercise program consisted of three months of supervised hospital-based treadmill walking with the training intensity progressively increased on a weekly basis. Each session was one hour long, three times per week. After 12 weeks, treated subjects increased maximal walking time by 123%, maximal oxygen consumption by 30%, and pain-free walking time by 165%. Controls had a 20% increase in maximal walking time but no change in any other measures of treadmill exercise performance. On entry to the training study, all patients reported signi cant dif culty walking de ned distances and speeds. After training, there were signi cant improvements in walking speed and distance in the treated group only. Thus, the training program resulted in increased patient-reported walking ability in the community setting in addition to the improvements in treadmill walking observed in standardized laboratory conditions.
In another trial, 29 men with disabling claudication were randomized to one of two exercise programs (treadmill training versus strength training) or a control group. 2 0 Patients initially either received 12 weeks of supervised walking exercise on a treadmill, 12 weeks of strength training, or 12 weeks without exercise (control). After 12 weeks, the patients in the treadmill training program received an additional 12 weeks of treadmill training. Twelve weeks of strength training were followed by 12 weeks of treadmill training. Those patients initially randomized to the control group subsequently received combined strength and treadmill training for 12 weeks.
After the rst 12 weeks, patients in the treadmill-trained group had a 74% increase in maximal walking time, as well as improvements in maximal oxygen consumption and a prolonged pain-free walking time. The physical activity level of treadmill trained patients increased by 31% and general physical functioning measured by Medical Outcomes Study SF-36 improved by 28%. 2 0 After 12 more weeks of treadmill exercise in this group, a total 128% increase in maximal treadmill walking time had occurred. Improvements in questionnaire scores were maintained, and the ability to walk distances and climb stairs was also improved. Following 12 weeks of strength training, patients improved in maximal walking time only with no change in maximal oxygen consumption. Improved patient-reported walking speed and stair climbing ability was observed in this group as well, though improvements were less than those observed in the supervised treadmill training group.
Control subjects showed no change in treadmill or community-based functional variables at 12 weeks of followup. 2 0 The combined strength and treadmill training program which the controls received after the rst 12 weeks improved maximal exercise performance to a degree similar to that observed with 12 weeks of treadmill training alone, with minimal bene ts to functional status measured by questionnaire. Thus, a supervised treadmill walking exercise program effectively improved exercise performance and functional status in patients with claudication, with continued improvement over 24 weeks of training. Importantly, improvements in questionnaire measurements were associated with improvements in treadmill walking. However, changes in treadmill or questionnaire measured variables were not associated with changes in ABI.
Surgery or angioplasty
Persons with severe claudication that limits their home, leisure or occupational activities and that is unresponsive to other medical treatments may be candidates for surgical or percutaneous transluminal angioplasty (PTA) revascular´ization. Bypass therapy for claudication is associated with improved functional status but has higher shortterm costs in terms of morbidity, mortality and health care resources. In addition, a subgroup of patients undergoing bypass for claudication will ultimately end up with CLI following eventual bypass occlusion, and require additional procedures with a greater risk of limb loss than if initially managed without surgery. Thus, other effective means including exercise rehabilitation and pharmacologic therapies are frequently used in the treatment of claudication and the majority of persons with claudication do not undergo a surgical procedure.
A study evaluating treadmill exercise performance and functional status in patients with claudication who received peripheral bypass surgery revealed that these measures were substantially improved by the surgery. 2 3 Patient improvements in treadmill walking time of 100% were accompanied by a 200% improvement in patient reported ability to walk distances and 100% in reported ability to walk at faster speeds as well as improvements in claudication symptoms. Importantly, with surgical revascularization, there was not a linear correlation with magnitude of ABI improvement and degree of improved treadmill walking distance and speed.
A randomized study comparing PTA and medical treatment in patients with claudication showed that PTA improved treadmill walking more than conventional treatment in association with improvements in the pain score of the Nottingham Health Pro le questionnaire 2 4 (Appendix I). However, of the patients screened (600) only 62 patients were found to have suitable lesions for this treatment (short segment stenoses in isolated arterial segments). Another study evaluated functional status and quality of life in 29 patients with claudication before and after PTA. 2 5 This study found that following PTA, perceived health state, mobility, usual activities, pain and mood all improved signi cantly.
Pharmacologic intervention
Development of drugs to treat claudication has become a major effort over the last 10 years. Many types of drugs have been studied, with some agents proving effective, some ineffective in trials, and some still in development.
Pentoxifylline, the rst agent to be approved by the US Food and Drug Administration (FDA) to treat claudication improves red cell deformability, lowers brinogen levels and decreases platelet aggregation. It is considered minimally effective, for in controlled trials, it produced a 22% improvement over placebo in walking distance prior to the onset of claudication and a 12% improvement in the maxi-mal walking distance. 2 6 Functional status questionnaires were not used in these trials.
Cilostazol is to date the only other drug to gain FDA approval for the indication of treating intermittent claudication since pentoxifylline was approved. Cilostazol belongs to the class of drugs called phosphodiesterase inhibitors. A meta-analysis examining the effects of cilostazol on walking distances in over 1700 patients with claudication reported improvements in measures of functional status and health-related quality of life, particularly in terms of patient-reported community-based walking and physical function. 2 7 These changes were concordant with a maximal walking distance improvement more than twice placebo in the 100 mg BID group. This drug cannot be used in patients with heart failure because of a reported class effect.
Other promising agents are currently in development including l-carnitine, an important cofactor for skeletal muscle intermediary metabolism during exercise. Carnitine is required for the mitochondrial oxidation of long-chain fatty acids, and also helps to maintain normal cellular metabolism under conditions of metabolic or hypoxic stress. 2 8 Patients with PAD have been shown to accumulate acylcarnitines (intermediates of oxidative metabolism) in their skeletal muscle, 2 9 which is directly correlated with impaired exercise performance.
A double-blind, dose titration study was conducted to evaluate the ef cacy of propionyl-l-carnitine (PLC) in 245 patients with claudication. 3 0 Maximal walking time improved in persons taking the active drug versus placebo. Quality of life was measured using the McMasters Health Index questionnaire 3 1 (Appendix I). It was found that patients who received the drug had a higher global score than those who received placebo due to an improvement in emotional domains. The physical function score tended to improve although it did not reach signi cance, possibly because many of the items in this category relate to selfcare activities, not necessarily affected by claudication.
Future directions
There are remaining questions about functional status and quality of life in patients with claudication. One major area of interest would be to directly compare the existing treatment modalities in terms of their effects on functional status and quality of life. Research has shown that claudication affects aspects of quality of life in addition to functional status, including feelings of social isolation, inadequacy, abnormality, limitation of freedom and a perception of being a burden on friends and family. 1 9 Despite this, assessment is often focused primarily on physiological and functional outcomes. Patients with critical limb ischemia Paradoxically, although these patients are clearly the most impaired of all PAD populations, there is less quanti ed information about their functional status and health-related quality of life than with the other two groups. In part, this may be because patients are often not clinically stable, the treatments offered this population entail signi cant morbidity, and the outcomes for this frequently end of life population are very complex. A reasonable outcome for one patient may not be the same as for another patient for a number of reasons. For example, healing of wounds and absence of pain at the price of a major amputation and being primarily wheelchair bound may be the best option for an elderly patient with CLI and oxygen-dependent chronic obstructive pulmonary disease, but is not an acceptable trade-off functionally for a younger patient in limb threat due to a failed bypass for claudication.
The majority of the available data for functional outcomes in patients with CLI are limited to clinical series with or without historical controls. There are few randomized trials, and those that have been performed were either pharmaceutical trials or focused on technical aspects of operative therapy (bypass conduit, preoperative imaging modalities, type of peri-or postoperative adjunctive antithrombotic therapy, etc.). Existing evidence for functional outcomes in patients with CLI can be divided into two basic groups: surgeon observation and patient reporting. Surgeon-observed outcomes most often historically reported with the most comprehensive data are perioperative mortality, lower extremity arterial bypass graft patency, limb salvage and long-term patient survival. Other surgeon-observed data include incision and foot wound healing rates, and incidence of postoperative lymphedema. For series examining major limb amputation, similar endpoints would be perioperative mortality, healing of transtibial (BKA) or transfemoral amputation (AKA), need for secondary operations to achieve healing, rate of ultimate BKA failure and conversion to AKA, and long-term patient survival.
In contrast, patient-reported information has included ambulatory status and independence or outcomes via functional outcome questionnaire tools. Existing literature reports typically have consisted of small clinical series (both prospective and retrospective) of patients pre-and postoperative from lower extremity revascularization and primary amputation. Problems with the available data of this type include a potentially signi cant selection bias (many of the patients with the worse clinical outcomes may refuse to participate or die prior to the follow-up interval), variable tools used that are not easily comparable, and small numbers of patients examined using these methods.
It is important to understand that the study of functional outcomes in CLI is in its infancy. The majority of the surgeon-observed outcomes above are markedly different than those discussed in the previous sections. Traditionally, limb salvage is considered the ideal goal for patients with CLI and this goal is often aggressively pursued whenever possible technically. However, in the last decade more data has accumulated demonstrating that signi cant morbidity is associated with universally aggressive limb salvage. Patients with CLI have limited survival rates, and much of their care must be considered palliative in nature. Due to the palliative nature of this care, weighing potential func-tional bene ts of interventions against the signi cant morbidity accrued is critical to improve the care of this population.
Patient-reported outcome studies are small in number compared with data presented in prior sections. The tools used are not uniform and even the interpretation of ndings is not uniform. Many patients with CLI have dif culty participating in longitudinal functional studies due to the impact of their comorbid diseases, changes in clinical course, and frequently poor socioeconomic status. This leads to many patients with incomplete follow-up information. Importantly though, CLI clearly affects more than the limb. The degree to which CLI impairs an individual's quality of life cannot simply be extrapolated from the clinical indicators of arterial insuf ciency, but is akin to cancer patients 'in the terminal phases of illness', perhaps due in part to the signi cant comorbidities present in the population. 3 2 -3 4 Nonoperative therapy Historically, patients with CLI were assumed to progress inevitably to limb loss without prompt revascularization. Clearly, patients with progressive gangrenous changes and constant ischemic pain have an unstable clinical situation requiring prompt intervention if limb loss is to be avoided. 3 5 However, abundant clinical experience indicates patients with CLI and intermittent rest pain may improve noticeably during periods of presumed improved cardiac hemodynamics and patients with small ulcerations may heal with protective dressings alone.
A single study from Brazil used quality of life measures to examine patients with CLI treated conservatively. 3 4 A total of 31 patients presenting with CLI were assigned to conservative therapy. At the end of one year, only 19 patients ultimately remained in the conservative arm of the study (the remainder underwent amputation, bypass or died). However, this small group of patients did demonstrate an improvement in their scores over time.
Revascularization
Currently, most patients presenting with CLI are offered some form of revascularization. 3 6 ,3 7 Thirty-day operative mortality rates have been reduced to less than 5%. 3 8 -4 1 Two primary endpoints reported include graft patency (60% or greater at ve years) and limb salvage (80-90% at ve years). Wound complications occur in up to 25% of patients. 4 2 -4 4 Healing times for incisional and foot wounds are often measured in months rather than weeks. Functional outcomes that address consistent issues in the CLI population include pain, physical function and mobility. However, assessing functional outcomes of revascularization in PAD patients as a group is dif cult because of the complex and widely differing courses that patients can follow. A universally consistent data point in all surgical series in CLI is the 50-60% ve-year patient survival rate, emphasizing the palliative nature of most CLI care. 4 0 , 4 5 Published reports using quality of life tools to measure outcomes following revascularization for CLI are presented in Table 3 . Interestingly, there would appear to be little difference in quality of life between patients operated on for rest pain versus tissue loss. 3 including self-reported physical function and mobility measures in other tools, improve. There appears to be a trend of worse functional outcome in those patients who fail revascularization and refuse amputation compared with those who undergo secondary amputation (calling in to question limb salvage rates as an isolated marker of success). However, the data set is small and incomplete, due to a variety of factors mentioned previously. Technical success (patency and limb salvage) varies widely from series to series, further confounding any global interpretation. Timing of the postoperative assessment is critical as many parameters continue to improve and only reach a peak at the 3-6 month postoperative period. The need for this sequential evaluation adds to the dif culty in studying this population after interventions. Patients with CLI tend to deteriorate in global function when followed for over a year, consistent with their signi cant comorbidities and poor survival. Finally, the tools used vary. All of these issues help to explain the failure of consensus in the published data.
Amputation
More data regarding functional outcomes in patients undergoing major amputation have been accumulated than with revascularization, possibly because much of the postoperative care from rehabilitation teams is focused on function. The incidence of major amputation has decreased slightly in the last decade, probably due to increases in limb salvage revascularization procedures. 4 6 The ratio of BKA to AKA is approximately one and has not changed in several decades. Primary BKA healing rates vary widely (30-90%). 4 7 -4 9 Up to 30% of patients who fail to heal will undergo a repeat amputation to save the knee joint and half of these will ultimately require an AKA. In contrast, the primary healing rate for an AKA is a more consistent 70% with 90% ultimately healing despite further procedures. 5 0 Amputations are major operations in an extremely ill, end-stage population. Due to the extensive comorbidities of the modern CLI population undergoing major limb amputation, prosthetic use and eventual ambulation is very limited. This is not surprising, as walking energy needs increase over bipedal gait by 30 and 60% to ambulate with a below-or above-knee prosthesis, respectively. 5 1 A review by Houghton et al summarizes the issue. 5 2 Four hundred forty major amputations (BKA/AKA ratio roughly one) were performed in eight major London hospitals over a two-year period. Seventy-ve patients (17%) died prior to discharge. One hundred thirteen were not considered rehabilitation candidates, with 252 referred to prosthetics/rehabilitation. At two years, 54 more patients had died and 19 had become non-ambulatory for non-vascular reasons (stroke, heart failure, etc.). Of the 179 remaining patients, 52 could walk brie y inside their home, and 21 could walk outside their home. In summary, in CLI it appears less than 50% of BKA patients ever walk postoperatively, and the majority are limited to walking for small distances in their homes. Any ambulation following AKA for CLI appears negligible. A question that remains relatively unanswered is whether limited ambulation post amputation converts large numbers of patients with CLI from an independent to a structured living situation. Recent data would indicate that frequently patients remain independent despite limb loss and lack of ambulation. 5 3 The few studies summarizing functional outcomes of primary amputation in patients with CLI using functional assessment tools are presented in Table 4 . These data demonstrate reduction in mobility measures, but also improvements in pain scores and anxiety. The majority of patients in these studies had BKAs with the typical number of reoperations/AKA conversions.
Future directions
Remaining questions for functional outcome in CLI include: Do we need a different functional assessment tool for use in this unique population? Are there subgroups of patients with CLI who would be equally served with a primary amputation rather than aggressive attempts at limb salvage? What clinical variables predict this potential subgroup? What level of morbidity makes the negative functional impact of a more durable therapy (surgery) outweigh 
Appendix I: Measuring functional status
When describing the status of functional status/quality of life assessment in the various stages of PAD, it is important to brie y describe some of the major tools that are used to evaluate function in patients with PAD.
Physical measures
Treadmill testing Serial treadmill testing is an objective means of assessing changes in performance in the patient with claudication. Importantly, in contrast to treadmill testing in cardiac patients, exercise testing protocols, which can be used in PAD patients, are less strenuous given the severe walking limitations, i.e., slower speed and less rapidly increasing grade. The two measures most commonly used to evaluate exercise performance on the treadmill are claudication-free walking time or distance (initial claudication distance -ICD) and maximal, claudication-limited walking time or distance (absolute claudication distance -ACD). The latter measure is used most frequently in clinical trials as the primary endpoint.
Six-minute walk test
The 6-minute walk test 6 8 has been shown to be highly reproducible, valid and sensitive to change in patients with claudication. In addition, there is a strong correlation with measures of treadmill walking in these patients. An advantage of this method is the lack of need for special equipment. Some studies suggest that this method may better approximate community walking in older patients than does treadmill walking. 1 1 Vertical accelerometer Another measure of walking performance validated in the PAD population is the vertical accelerometer, a measure of physical activity. The accelerometer has been validated against treadmill walking in several studies. McDermott et al 6 8 and Siemanski et al 6 9 have shown that the Caltrac accelerometer is a valid measure of distance walked in patients and in turn have validated two physical activity questionnaires against the accelerometer. 7 0 -7 2
Usual walking speed and the summary performance The summary performance score combines data on walking velocity, time for ve repeated chair rises, and standing balance to achieve a score on a 0-12 scale (12 = best). Performance on these objective measures of lower extremity functioning predicts risk of nursing home place- ment, loss of mobility, and loss of the ability to perform activities of daily living among older community-dwelling populations. These functional outcomes measure maximum performance and are objective measures of lower extremity functioning. Previous study shows that lower ABI levels are associated with poorer performance on these functional outcome measures. 7 3 -7 5 Questionnaire assessments In order to enable comprehensive evaluation of functional status in the PAD population, community-based measures of patient-reported functioning (i.e., questionnaires) should be incorporated in addition to treadmill tests. Alternatively, some of the questionnaires can be used as the primary measure of functional status when objective measures of functioning are not possible. This is because some of the questionnaires have been validated against measures of treadmill walking. As with treadmill testing, criteria by which to judge the utility of a questionnaire must be established. A questionnaire should be valid, reliable, sensitive to change and feasible in a busy clinical practice, so that both patient and health care professional are easily able to work with the instrument. 7 6 Primarily, two types of questionnaire have been used in the patient with claudication. Functional status questionnaires have been used to evaluate aspects of patientreported walking per se as well as the ability to carry out normal activities. 7 7 Quality of life questionnaires evaluate such qualities as life satisfaction, morale and happiness. The term quality of life addresses the patient's perceived well-being and function in emotional and social terms.
Disease-speci c functional status questionnaires
The Walking Impairment Questionnaire (WIQ) has been used to assess the ability of PAD patients to walk de ned distances and speeds, as well as to climb stairs. 6 In addition, the questionnaire also evaluates claudication severity and the presence of other (nonclaudication) symptoms that could potentially limit walking. The WIQ has been used to evaluate changes in community-based walking ability resulting from an exercise-training program as well as from peripheral bypass surgery. It has also been used as a functional measure in multiple trials of pharmacologic agents in claudication therapy. The WIQ has been validated against measures of treadmill walking (ACD and ICD) as well against the 6-minute walk test, 4-meter walking speed, and the ankle brachial index. 6 ,7 8 Combined functional status and quality of life questionnaires The Medical Outcomes Study SF-36 (MOS SF-36) questionnaire has been validated and found to be reliable in large populations of healthy and diseased individuals. 6 ,7 9 ,8 0 It is used to measure multiple domains of patient-reported functional status. These domains are also aggregated into a physical component score and a mental component score. Elements from the mental component are not usually improved by treatments that increase walking ability.
Other questionnaires have been used in the PAD population, although these have not been validated against objective measures of functioning. The Nottingham Health Pro le (NHP) has been widely used to evaluate the patient with claudication, 7 7 ,8 1 especially at European centers. It also appears to have been used widely in CLI patients ( Table  2 ). The questionnaire is similar to the MOS SF-36 in that it evaluates physical, social and emotional health domains so that functional status and quality of life are both evaluated. Other questionnaires of this combined type which have been used in studies of claudicating patients are the European Quality of Life Scale (EuroQol) 8 Quality of life questionnaires The Impact of PAD on Quality of Life Questionnaire (PADQOL) is a disease-speci c questionnaire which evaluates patients' views of dif culties with diagnosis and management of disease, limitations in physical functioning, limitations in social functioning, symptom experience, compromise of self, uncertainty and adaptation. 1 9 The questionnaire results in a weighted score ranging from 0 to 20. This questionnaire takes approximately 10-15 minutes to complete. The PADQOL total score correlates with the WIQ distance and speed scores and the SF-36 subscale scores. Further validation of this instrument is ongoing.
